Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ardelyx's Tenapanor Data Challenge Phosphate Binders In Hyperphosphatemia

Executive Summary

Although rate of diarrhea was higher for first-in-class tenapanor compared to phosphate binders in the first pivotal trial, drop-out rate is what counts and that was lower, say analysts, happy with the overall dataset.

Advertisement

Related Content

Ardelyx's Adjusted Trial Design May Expedite NDA Filing For Lead Candidate

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register